EPO and chronic kidney disease: The mechanism of action on anemia is mainly to promote the synthesis of EPO (Gerl et al., 2015) and improve iron metabolism (Akizawa et al., 2017; Chen et al., 2017), and it is also beneficial to the cardiovascular aspects of CKD patients (Holdstock et al., 2016; Provenzano et al., 2016).